Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

This study is testing a new combination treatment — a drug called JS207 (which targets two cancer-related proteins at once) paired with chemotherapy — for people with advanced lung cancer that has come back or spread. **You may be eligible if...** - You are between 18 and 75 years old - You have a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that is advanced, has spread, or has returned - Your lung cancer cannot be treated with surgery or radiation alone - Your tumor has a specific genetic mutation ("driver gene") and your cancer stopped responding to targeted therapy (TKI drugs) - A lab test shows your tumor has a protein called PD-L1 (score of 1% or more) - You are in generally good health and can perform daily activities **You may NOT be eligible if...** - You have small cell lung cancer or squamous cell cancer components - You have cancer in the brain that is causing symptoms - You have a history of autoimmune disease or a weakened immune system - You have active tuberculosis, hepatitis B, or hepatitis C - You have been diagnosed with another cancer in the past 5 years - You have uncontrolled high blood pressure or a history of severe bleeding Talk to your doctor to see if this trial is right for you.